Stephen P. MacMillan

Stephen P. MacMillan, age 61 as of January 2025 , has built a distinguished career underpinned by a strong educational foundation, holding a Bachelor of Arts in economics from Davidson College and completing the Advanced Management Program at Harvard Business School.

He began his leadership journey at HOLX when he joined as President, CEO, and a director on December 6, 2013 and later expanded his role by being elected Chairman in June 2015. His tenure at the company has been marked by strategic decision-making and transformational leadership.

Before joining HOLX, he garnered extensive experience in the healthcare and consumer industries with key roles at Stryker Corporation, Pharmacia Corporation, Johnson & Johnson, and sBioMed, LLC. His broad expertise and commitment to operational excellence continue to drive HOLX’s growth and innovation, making him a respected leader in the industry.

Non-Equity Incentive Plan (Annual Cash Incentive Awards)

• Evaluation Period: Fiscal 2024.
• Actual Results: Overall payout reached 109% of the target; Adjusted Revenue achieved 91% of target and Adjusted EPS 134% of target.

Performance Stock Units (PSUs)

• Performance Metrics:
  • FCF PSUs: Based on cumulative adjusted Free Cash Flow; no vesting if performance is below $2,100M.
  • ROIC PSUs: Tied to three-year average adjusted ROIC.
  • TSR PSUs: Determined by relative Total Shareholder Return with thresholds at the 25th, 50th, and 95th percentiles.
• Vesting Schedule: Cliff vesting at the end of three years (November 2026).
• Grant Date: November 14, 2023.
• Evaluation Period: Three years (Fiscal 2024–2026).

Long-Term Incentive Award Grants

• Vesting: RSUs vest in three equal annual installments; stock options vest in four equal annual installments.
• Grant Details:
  • Grant Date: November 14, 2023.
  • Grant Date Fair Values: $2,937,454 for stock awards and $2,937,477 for option awards.
  • Grant Date Stock Price: $71.94 per share.
• Evaluation Period: Three years for the PSUs.